Communication sur les risques et participation Communautaire
Mensagens para Comunicação dos Riscos e Envolvimento da Comunidade
It is intended for use among clinicians taking care of moderate to severe COVID-19 cases.
The COVID-19 outbreak has brought with it the need for improved critical care for patients who develop severe disease. The majority of COVID-19 patients present with mild to moderate illness, 15% develop sever...e illness and about 5% develop critical conditions needing intensive care unit (ICU) care, requiring noninvasive or invasive ventilation
more
Facilitator's Guide
Refresher Training Module for Health Care Providers implementing the MISP
Inter-agency Working Group on Reproductive Health in Crises Training Partnership
Web annex 6: Injectable prostaglandins versus
placebo or no treatment
Evidence to Decision Framework
Web annex 5: Oxytocin and ergometrine versus placebo or no treatment
Evidence to decision framework
Web annex 2: Carbetocin versus placebo or no treatment
Evidence to decision framework
The recommendation in this document thus supersedes the previous WHO recommendation for the prevention of PPH as published in the 2012 guideline, WHO recommendations for the prevention and treatment of postpartum haemorrhage.
WHO published guidance for clinicians and health care decision-makers on the use of corticosteroids in patients with COVID-19.
We recommend systemic corticosteroids for the treatment of patients with severe and critical COVID-19. We suggest not to use corticosteroids in the treatment of patients ...with non-severe COVID-19 as the treatment brought no benefits, and could even prove harmful. Treatment should be under supervision of a clinician.
Corticosteroids are listed in the WHO model list of essential medicines, readily available globally at a low cost. WHO encourages countries to maintain sufficient stocks of corticosteroids to treat COVID-19 and the other disease for which they are effective, while not maintaining excessive stocks which could deny other countries access.
more
The recommendation in this document thus supersedes the previous WHO recommendation for the prevention of PPH as published in the 2012 guideline, WHO recommendations for the prevention and treatment of postpartum haemorrhage.
Nota INformatIva Nº 13/2020 - SE/GaB/SE/mS
September 2020
ESTA NOTA INFORMATIVA SUBSTITUI A NOTA INFORMATIVA Nº 11/2020-SE/GAB/SE/MS, DE 15 DE JUNHO DE 2020, QUE SUBSTITUIU A NOTA INFORMATIVANº 9/2020-SE/GAB/SE/MS, DE 20 DE MAIO DE 2020
based on information as at 28 February 2021
Rapid Policy Brief Series Series 14: COVID-19 and hypertension
Sur la base des informations disponibles au 28 février 2021
Rapid Policy Brief Series Series 14: COVID-19 and hypertension
— com base na informação disponível a 28 de Fevereiro de 2021
Rapid Policy Brief Series Series 14: COVID-19 and hypertension